Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04851743
Other study ID # CBAS-2018-11B
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 10, 2021
Est. completion date July 6, 2021

Study information

Verified date September 2020
Source Universitat Internacional de Catalunya
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Trigger points (TrPs) are a common musculoskeletal cause of local and referred muscle pain, as well as local inflammation in the muscle and fascia. From a clinical and sensory viewpoint, TrPs may be classified as active or latent. The principal difference is the reproduction of symptoms experienced by an individual (active) with or without stimulation. Local and referred pain elicited from latent TrPs may be transient in duration upon stimulation, and latent TrPs may be present without spontaneous symptoms. Both active and latent TrPs induce motor dysfunctions such as stiffness, restricted range of motion, and accelerated fatigability in the affected muscle. The interrater reliability of manual identification of latent TrPs in the calf muscles has been found to range from small to moderate. The clinical relevance of latent TrPs has increased in the last decade,4 and some studies have investigated the effects of treating them. Among all manual therapies targeted to latent TrPs, ischemic compression, or TrP pressure release, is the most commonly used. Although TrPs may affect any muscle, the gastrocnemius muscle may be the most susceptible in the lower extremity to developing them. It has been reported that 13% to 30% of the asymptomatic population has latent TrPs in these muscles, and their presence may affect sport practice. The purpose of this study will be to evaluate changes in neuromuscular function, pain perception, and basic physical properties in myofascial trigger points (TrPs) after a single treatment session of dry needling in the gastrocnemius muscle. A randomized within-participant clinical trial with a blinded assessor will be conducted. 50 asymptomatic volunteers (100 gastrocnemius-muscle) with MrPs gastrocnemius-muscle TrPs will bilaterally explored. Each extremity will be randomly assigned to the control group (no treatment) or the experimental group (60 seconds of dry needling over each TrP). Neuromuscular function of the gastrocnemius muscle will be assessed using a MyotonPro and a tensiomyography. Muscle flexibility will be analyzed using the lunge test and the passive ankle range of motion. The strength will be determined with a handheld dynamometer (MicroFET2). Pain perception will be analyzed with a 0-to-10 numerical pain rating scale and determination of pressure pain thresholds over each latent TrP.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date July 6, 2021
Est. primary completion date July 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - A TrP will be diagnosed using the following criteria: palpable taut band, presence of a painful spot in the taut band, and referred pain on palpation of the spot. Exclusion Criteria: - Participants were excluded if they reported any pain symptoms in the lower extremities in the previous year. - They were also excluded if they presented previous surgical interventions, previous lower-extremity injury, any underlying medical disease, pregnancy, or muscle soreness after vigorous exercise.

Study Design


Intervention

Other:
Dry needling
The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.

Locations

Country Name City State
Spain Albert Pérez-Bellmunt Sant Cugat del Vallès Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Universitat Internacional de Catalunya

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neuromuscular Function (MyotonPro device) (Hz) The Neuromuscular function will be assessed with a handheld MyotonPro myotonometry device, which will be placed on the skin, perpendicular to the surface of the belly of each gastrocnemius muscle, with the participant prone. The device will then lowered into the measurement position and held steady while it automatically conducted the predefined measurement series. The program consist of 3 single measurements with a recording interval of 1 second for each muscle. The average valuevfor each site will used in subsequent analyses. The reliability of the MyotonPro device has been reported to range from good to excellent (intraclass correlation coefficient = 0.8-0.93). Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
Primary Tensomyography (m/s) The Tensomyography evaluation will be done by using a Dc-Dc Trans-TekĀ® transductor (GK 40, Panoptik d.o.o., Ljubliana, Slovenia) that will be perpendicularly placed to the gastrocnemius belly. Two self-adhesive electrodes (TMG electrodes, TMG-BMC d.o.o., Ljubljana, Slovenia) will be placed equidistant, proximal (anode) and distal (cathode) to the sensor, with an inter-electrode distance of 5 cm. Patient will be placed in prone position with a foam Electrical stimulation was applied through a TMG-100 System electrostimulator (TMG-BMCd.o.o., Ljubljana, Slovenia). The amplitude will be progressively increased from 20 to 100 mA by 20 mA increments until there will be no further increase in maximal radial displacement or maximal stimulator output was reached (i.e 110mA) (20). Ten seconds rest will be given between the stimuli to minimize the effects of fatigue and potentiation. The meters per second of muscle contraction with the electrical stimulus will be measured. Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
Secondary Pressure Pain Threshold (Kg/cm2) The pressure pain threshold is the amount of pressure that is first perceived as painful. In this study, it will be assessed over the gastrocnemius TrP with a handheld mechanical pressure algometer (Trigger Plus, Pal- patronic, Hagen, Germany). Pressure will be applied at a rate of 10 N/cm2/s until the participant first reported a painful sensation. This procedure has shown good intrarater reliability. Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
Secondary Pain with numerical pain rating scale Participants will be also asked to rate their pain perception during the pressure pain threshold on an 11-point numerical pain rating scale (0 = no pain, 10 = maximum pain). Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
Secondary Ankle Dorsiflexion Range of Motion (º) Active ankle dorsiflexion range of motion will be assessed with the dorsiflexion lunge test. The test will be performed by placing the foot perpendicular to a wall and lunging the knee toward the wall. The foot will be moved further away from the wall until the maximum range of dorsiflexion was achieved. In order for the heel to not lift off of the floor, the examiner will place a band under the heel and applied tension.
The angulation from the tibia bone to the floor will be measured. The dorsiflexion lunge test has shown good intrarater and interrater reliability (intraclass correlation coefficient = 0.97).
Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
Secondary Muscle Strentch (Newtons) A dynamometer (MicroFET2, Hoggan Scientific, Salt Lake City, Utah) was used for isometric muscle-strength testing. All participants will barefoot during the testing procedure. Peak force will be measured by the dynamometer to the nearest 0.1 N. Contractions will be sustained for 3 seconds while the examiner applied unmoving resistance. Both gastrocnemius-testing will be repeated for 3 trials, with a 5-second rest between them. The mean of the 3 trials will be considered in the analysis. Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06029413 - Myo vs. Myofascial Injection for Myofascial Trigger Points N/A
Recruiting NCT04985578 - Effects on Muscle Activity After Dry Needling in Myofascial Trigger Points of the Gastrocnemius Muscles N/A
Completed NCT05546203 - Trigger Point Treatment in Chronic Pelvic Pain N/A
Completed NCT06258070 - Clinical Performance of Therapeutic Use of BTX for Bruxism N/A
Completed NCT04531306 - An Analysis of Kinesio® Tape on Myofascial Pain Syndrome of the Iliotibial Band N/A
Completed NCT03708107 - Percutaneous Microelectrolysis (MEP) Versus Ischemic Compression in Miofascial Trigger Points N/A
Completed NCT02913976 - Changes on Pain and Range of Motion by the Use of Kinesio Taping in Patients Diagnosed With Cervical Pain N/A
Completed NCT02913963 - Changes on Pain and Range of Motion by the Use of Kinesio Taping in Subjects With Myofascial Trigger Point N/A
Completed NCT04719689 - Comparison of Dry Needling and Dry Cupping in Positional Fault of Pelvis N/A
Recruiting NCT05792111 - Caudal Epidural Steroid and Trigger Point Injection Phase 4
Completed NCT03704311 - Evaluation of Mitochondrial Function in Myofascial Trigger Points Cohort Pilot Study Using High-resolution Respirometry N/A
Recruiting NCT05429827 - The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome N/A
Recruiting NCT05151510 - Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department Phase 4
Completed NCT05396196 - An Analysis of Kinesio® Tape With Manual Fascial Glide Application on Trigger Points in The Iliotibial Band N/A
Completed NCT05664165 - The Efficiency of Dry Needling and Cold Spray-stretching Treatments N/A
Completed NCT01250184 - Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Phase 4
Enrolling by invitation NCT03941054 - Myosfascial Trigger-Points and Effects on Neuromuscular Response N/A
Completed NCT04993118 - Integration of Neuromuscular Inhibition Technique On Trapezius Trigger Points. N/A
Not yet recruiting NCT06338514 - The Effectiveness of Dry Needling Treatment in Patients Diagnosed With Dorsal Myofascial Pain Syndrome. N/A
Recruiting NCT06013644 - Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome Early Phase 1